Unnamed stage
$2.5m
Andrew Forrest doubles down on therapeutic ecstasy biotech Emyria
Therapeutic psychedelics biotech Emyria has banked $2.5 million via a share placement co-led by Sixty Two Capital and Taylor Collison, with follow-on from Andrew Forrest's Tenmile, funding MDMA- and psilocybin-assisted therapy and cannabinoid trials.